Sunday, November 29, 2020
LG's North American Innovation Center will be based in
Silicon Valley, California, with the task of exploring new business
opportunities and cooperating with leading tech firms there, the company said.
Rhee Sokwoo, who served as an associate director at the U.S. National Institute of Standards and Technology (NIST), will head the center, it added.
In its latest reconfiguration of business units, LG also announced that it will establish a business incubation center to support various new business opportunities.
LG will also set up "CX Lab" that will be managed directly under the CEO to bolster design capability related to user experience. LG added its robot business center will be now managed under its business solutions unit.
Meanwhile, the electronics giant promoted a total of 56 executives in its annual personnel reshuffle, up from 49 last year.
The company named Lyu Jae-cheol, who has been leading its living appliance business, as new chief for its home appliance & air solution business division.
CYBER MONDAY DEAL:
Wednesday, November 25, 2020
Qualcomm to hold the 5th annual Tech Summit Digital 2020 on Dec 1-2, 2020. Snapdragon 875 some specifications.
More information on Qualcomm
Tuesday, November 24, 2020
LG Display’s transparent OLED panel is used for the window of a subway in China.
LG Display has expanded its “transparent OLED” business towards the Japanese market after it did so with the Chinese market.
Panasonic announced that it would begin selling 55-inch transparent OLED modules in Japan, Taiwan, Singapore, Australia, and New Zealand starting from this year. This OLED module is based on LG Display’s transparent OLED panel and is less than one centimeters in thickness.
“Panasonic’s module was developed to target B2B (Business to Business) digital signage market in its native country and the Asia-Pacific market.” said one industry official. “LG Display supplied transparent OLED panels that are the key to the module.”
Not only does Panasonic’s module maintains contrast ratio of video contents even in an environment where the intensity of illumination is strong, but it also assists in providing clear images and videos. Panasonic attached a dimming unit that electrically controls light transmittance on the back of the panel and applied a technology that switches the panel between transparent mode and shading mode.
For example, the shading mode that controls the light that passes through the back of the panel is activated by lowering the transmittance of the dimming unit in an environment where the intensity of illumination is strong.
Panasonic explained that there can be many uses with the module as it can be used in various places such as commercial facilities, transportation infrastructures, and public facilities. It also added that a large display screen can also be made by attaching many panels together.
“Development of communication infrastructures and diversification of contents are taking place rapidly,” said Panasonic. “We have decided to commercialize the module due to a rise in expectations towards transparent display that is able to display new images and videos.”
LG Display’s transparent OLED supply chain is expected to expand continuously as there are growing demands for transparent OLEDs globally.
It is reported that Xiaomi’s 55-inch transparent OLED TV, which is the first in the world, is also equipped with LG Display’s transparent OLED panel. It is likely that the same panel is used for Panasonic’s OLED module.
LG Display’s transparent OLED panels are also used for windows of subways in Beijing and Shenzhen. Disney plans to build a space for experimenting with transparent OLED panel within its establishment with LG Display.
Korea IT News.
Monday, November 23, 2020
According to Gina Maria Colvin Hill, who posted the above video on Youtube, Mia Schopen has captured several images of what appears to be a Starship (UFO) and it is coming into our atmosphere as filmed from the ISS. The ship is coming in and it is not a camera reflection.
IMHO the starship arrived in our atmosphere coming out from some kind of portal. Who knows.
Every kind of UFO or extraterrestrial visits have been happening for thousands of years, but maybe they are intraterrestrials who live underneath or underwater or inside a volcano. Just guessing.
Gina has a wonderful youtube channel where you can find a long playlist of her experiences finding UFO presence https://www.youtube.com/c/GinaMariaColvinHill555/about
Wednesday, November 18, 2020
SCIENCE: PFIZER/BIONTECH Primary efficacy analysis demonstrates BNT162b2 vaccine to be 95% effective against COVID-19. Press Release.
PFIZER AND BIONTECH CONCLUDE PHASE 3 STUDY OF COVID-19 VACCINE CANDIDATE, MEETING ALL PRIMARY EFFICACY ENDPOINTS
Wednesday, November 18, 2020 - 06:59am
- Primary efficacy analysis demonstrates BNT162b2 to be 95% effective against COVID-19 beginning 28 days after the first dose;170 confirmed cases of COVID-19 were evaluated, with 162 observed in the placebo group versus 8 in the vaccine group
- Efficacy was consistent across age, gender, race and ethnicity demographics; observed efficacy in adults over 65 years of age was over 94%
- Safety data milestone required by U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved
- Data demonstrate vaccine was well tolerated across all populations with over 43,000 participants enrolled; no serious safety concerns observed; the only Grade 3 adverse event greater than 2% in frequency was fatigue at 3.8% and headache at 2.0%
- Companies plan to submit within days to the FDA for EUA and share data with other regulatory agencies around the globe
- The companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021
- Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world
NEW YORK & MAINZ, Germany--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that, after conducting the final efficacy analysis in their ongoing Phase 3 study, their mRNA-based COVID-19 vaccine candidate, BNT162b2, met all of the study’s primary efficacy endpoints. Analysis of the data indicates a vaccine efficacy rate of 95% (p<0.0001) in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective), in each case measured from 7 days after the second dose. The first primary objective analysis is based on 170 cases of COVID-19, as specified in the study protocol, of which 162 cases of COVID-19 were observed in the placebo group versus 8 cases in the BNT162b2 group. Efficacy was consistent across age, gender, race and ethnicity demographics. The observed efficacy in adults over 65 years of age was over 94%.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201118005595/en/
There were 10 severe cases of COVID-19 observed in the trial, with nine of the cases occurring in the placebo group and one in the BNT162b2 vaccinated group.
To date, the Data Monitoring Committee for the study has not reported any serious safety concerns related to the vaccine. A review of unblinded reactogenicity data from the final analysis which consisted of a randomized subset of at least 8,000 participants 18 years and older in the phase 2/3 study demonstrates that the vaccine was well tolerated, with most solicited adverse events resolving shortly after vaccination. The only Grade 3 (severe) solicited adverse events greater than or equal to 2% in frequency after the first or second dose was fatigue at 3.8% and headache at 2.0% following dose 2. Consistent with earlier shared results, older adults tended to report fewer and milder solicited adverse events following vaccination.
In addition, the companies announced that the safety milestone required by the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) has been achieved. Pfizer and BioNTech plan to submit a request within days to the FDA for an EUA based on the totality of safety and efficacy data collected to date, as well as manufacturing data relating to the quality and consistency of the vaccine. These data also will be submitted to other regulatory agencies around the world.
“The study results mark an important step in this historic eight-month journey to bring forward a vaccine capable of helping to end this devastating pandemic. We continue to move at the speed of science to compile all the data collected thus far and share with regulators around the world,” said Dr. Albert Bourla, Pfizer Chairman and CEO. “With hundreds of thousands of people around the globe infected every day, we urgently need to get a safe and effective vaccine to the world.”
“We are grateful that the first global trial to reach the final efficacy analysis mark indicates that a high rate of protection against COVID-19 can be achieved very fast after the first 30 µg dose, underscoring the power of BNT162 in providing early protection,” said Ugur Sahin, M.D., CEO and Co-founder of BioNTech. “These achievements highlight the potential of mRNA as a new drug class. Our objective from the very beginning was to design and develop a vaccine that would generate rapid and potent protection against COVID-19 with a benign tolerability profile across all ages. We believe we have achieved this with our vaccine candidate BNT162b2 in all age groups studied so far and look forward to sharing further details with the regulatory authorities. I want to thank all the devoted women and men who contributed to this historically unprecedented achievement. We will continue to work with our partners and governments around the world to prepare for global distribution in 2020 and beyond.”
The Phase 3 clinical trial of BNT162b2 began on July 27 and has enrolled 43,661 participants to date, 41,135 of whom have received a second dose of the vaccine candidate as of November 13, 2020. Approximately 42% of global participants and 30% of U.S. participants have racially and ethnically diverse backgrounds, and 41% of global and 45% of U.S. participants are 56-85 years of age. A breakdown of the diversity of clinical trial participants can be found here from approximately 150 clinical trials sites in United States, Germany, Turkey, South Africa, Brazil and Argentina. The trial will continue to collect efficacy and safety data in participants for an additional two years.
Based on current projections, the companies expect to produce globally up to 50 million vaccine doses in 2020 and up to 1.3 billion doses by the end of 2021. Four of Pfizer’s facilities are part of the manufacturing and supply chain; St. Louis, MO; Andover, MA; and Kalamazoo, MI in the U.S.; and Puurs in Belgium. BioNTech’s German sites will also be leveraged for global supply.
Pfizer is confident in its vast experience, expertise and existing cold-chain infrastructure to distribute the vaccine around the world. The companies have developed specially designed, temperature-controlled thermal shippers utilizing dry ice to maintain temperature conditions of -70°C±10°C. They can be used be as temporary storage units for 15 days by refilling with dry ice. Each shipper contains a GPS-enabled thermal sensor to track the location and temperature of each vaccine shipment across their pre-set routes leveraging Pfizer’s broad distribution network.
Pfizer and BioNTech plan to submit the efficacy and safety data from the study for peer-review in a scientific journal once analysis of the data is completed.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
Monday, November 16, 2020
SCIENCE: MODERNA COVID-19 vaccine Phase 3 study met statistical criteria with an efficacy of 94.5%. Press Release.
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study.
The first interim analysis included 95 participants with confirmed cases of COVID-19
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov. 16, 2020--
They are an inspiration to us all. I want to thank the
Samsung is going to hold an Unpacked event on August 10, 2022, to unfold the new versions of foldable smartphones. The Galaxy Z Fold 4 and...
WorldWide Tech & Science. Francisco De Jesús. LG Debuts Dishwasher With TrueSteam™, Virtually Eliminating Pre-washing for Greater Ease....
A variety in Flash Drives portable memory are available now, from 128GB, 64GB and 16GB USB 3.0, that you can browse here below: PNY 12...
WorldWide Tech & Science. Francisco De Jesús. The Beats audio jacks are grounded compared with others audio jacks that bring interfer...
WorldWide Tech & Science. Francisco De Jesús. Despite the reports around the web say the new battery will make the device thicker, we ...
WorldWide Tech & Science. Francisco De Jesús. Sharp Begins Production of World's First LCD Panels Incorporating IGZO Oxide Semicon...
4GB Ram,16MP Camera,64-bit processor...The Samsung Galaxy S5 is coming! The Samsung Galaxy S5 might be months away from it's l...
WorldWide Tech & Science. Francisco De Jesús. Taiwan: Sony launches Alpha series A57 DSLR camera. Sony on April 10 announced the launc...
WorldWide Tech & Science. Francisco De Jesús. The GSMA announced that CEOs and senior executives from companies includi...